Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment

Chelsea Hardin, Rodney Pommier, Brett Lefleur, Terisa Jackson, SuEllen Toth-Fejel

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Dehydroepiandosterone sulfate (DHEAS) causes breast-cancer proliferation, even during tamoxifen or fulvestrant blockade. The purpose of this study was to determine possible mechanisms for this treatment failure. T-47D cells (estrogen receptor [ER] and progesterone receptor [PR] positive) were treated with fulvestrant (10 mol/L), tamoxifen (10 mmol/L or 0.0001 nmol/L), or vehicle and stimulated with DHEAS. Gene expression of ER, PR, insulin-like growth factor (IGF)-1 and -2, and insulin-like growth-factor binding protein (IGFBP)-1 through -4 was determined. ER and PR gene expression decreased by 1.3- and 4-fold with fulvestrant and DHEAS. ER expression decreased by 2.7-fold with 0.0001 nmol/L tamoxifen and DHEAS. ER and PR expression were unchanged by 10 nmol/L tamoxifen. IGF-1 and IGF-2 were not expressed. IGFBP-2 and -4 expression decreased by 1.9- and 1.6-fold after DHEAS stimulus, although this was not statistically significant. DHEAS exposure, even in the presence of tamoxifen and fulvestrant, induces changes in ER and PR gene expression that may be partially responsible for breast cancer progression.

    Original languageEnglish (US)
    Pages (from-to)426-428
    Number of pages3
    JournalAmerican Journal of Surgery
    Volume188
    Issue number4 SPEC. ISS.
    DOIs
    StatePublished - Oct 2004

    Fingerprint

    Tamoxifen
    Estrogen Receptors
    Sulfates
    Progesterone Receptors
    Breast Neoplasms
    Somatomedins
    Gene Expression
    Insulin-Like Growth Factor Binding Protein 4
    Insulin-Like Growth Factor Binding Protein 2
    Insulin-Like Growth Factor Binding Protein 1
    Treatment Failure
    fulvestrant

    Keywords

    • Breast cancer
    • Dehydroepiandosterone sulfate
    • Estrogen receptor
    • Fulvestrant
    • Insulin-like growth factor
    • Tamoxifen

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment. / Hardin, Chelsea; Pommier, Rodney; Lefleur, Brett; Jackson, Terisa; Toth-Fejel, SuEllen.

    In: American Journal of Surgery, Vol. 188, No. 4 SPEC. ISS., 10.2004, p. 426-428.

    Research output: Contribution to journalArticle

    Hardin, Chelsea ; Pommier, Rodney ; Lefleur, Brett ; Jackson, Terisa ; Toth-Fejel, SuEllen. / Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment. In: American Journal of Surgery. 2004 ; Vol. 188, No. 4 SPEC. ISS. pp. 426-428.
    @article{c2a9738c9db44b0793f71280c6956b5c,
    title = "Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment",
    abstract = "Dehydroepiandosterone sulfate (DHEAS) causes breast-cancer proliferation, even during tamoxifen or fulvestrant blockade. The purpose of this study was to determine possible mechanisms for this treatment failure. T-47D cells (estrogen receptor [ER] and progesterone receptor [PR] positive) were treated with fulvestrant (10 mol/L), tamoxifen (10 mmol/L or 0.0001 nmol/L), or vehicle and stimulated with DHEAS. Gene expression of ER, PR, insulin-like growth factor (IGF)-1 and -2, and insulin-like growth-factor binding protein (IGFBP)-1 through -4 was determined. ER and PR gene expression decreased by 1.3- and 4-fold with fulvestrant and DHEAS. ER expression decreased by 2.7-fold with 0.0001 nmol/L tamoxifen and DHEAS. ER and PR expression were unchanged by 10 nmol/L tamoxifen. IGF-1 and IGF-2 were not expressed. IGFBP-2 and -4 expression decreased by 1.9- and 1.6-fold after DHEAS stimulus, although this was not statistically significant. DHEAS exposure, even in the presence of tamoxifen and fulvestrant, induces changes in ER and PR gene expression that may be partially responsible for breast cancer progression.",
    keywords = "Breast cancer, Dehydroepiandosterone sulfate, Estrogen receptor, Fulvestrant, Insulin-like growth factor, Tamoxifen",
    author = "Chelsea Hardin and Rodney Pommier and Brett Lefleur and Terisa Jackson and SuEllen Toth-Fejel",
    year = "2004",
    month = "10",
    doi = "10.1016/j.amjsurg.2004.06.017",
    language = "English (US)",
    volume = "188",
    pages = "426--428",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "4 SPEC. ISS.",

    }

    TY - JOUR

    T1 - Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment

    AU - Hardin, Chelsea

    AU - Pommier, Rodney

    AU - Lefleur, Brett

    AU - Jackson, Terisa

    AU - Toth-Fejel, SuEllen

    PY - 2004/10

    Y1 - 2004/10

    N2 - Dehydroepiandosterone sulfate (DHEAS) causes breast-cancer proliferation, even during tamoxifen or fulvestrant blockade. The purpose of this study was to determine possible mechanisms for this treatment failure. T-47D cells (estrogen receptor [ER] and progesterone receptor [PR] positive) were treated with fulvestrant (10 mol/L), tamoxifen (10 mmol/L or 0.0001 nmol/L), or vehicle and stimulated with DHEAS. Gene expression of ER, PR, insulin-like growth factor (IGF)-1 and -2, and insulin-like growth-factor binding protein (IGFBP)-1 through -4 was determined. ER and PR gene expression decreased by 1.3- and 4-fold with fulvestrant and DHEAS. ER expression decreased by 2.7-fold with 0.0001 nmol/L tamoxifen and DHEAS. ER and PR expression were unchanged by 10 nmol/L tamoxifen. IGF-1 and IGF-2 were not expressed. IGFBP-2 and -4 expression decreased by 1.9- and 1.6-fold after DHEAS stimulus, although this was not statistically significant. DHEAS exposure, even in the presence of tamoxifen and fulvestrant, induces changes in ER and PR gene expression that may be partially responsible for breast cancer progression.

    AB - Dehydroepiandosterone sulfate (DHEAS) causes breast-cancer proliferation, even during tamoxifen or fulvestrant blockade. The purpose of this study was to determine possible mechanisms for this treatment failure. T-47D cells (estrogen receptor [ER] and progesterone receptor [PR] positive) were treated with fulvestrant (10 mol/L), tamoxifen (10 mmol/L or 0.0001 nmol/L), or vehicle and stimulated with DHEAS. Gene expression of ER, PR, insulin-like growth factor (IGF)-1 and -2, and insulin-like growth-factor binding protein (IGFBP)-1 through -4 was determined. ER and PR gene expression decreased by 1.3- and 4-fold with fulvestrant and DHEAS. ER expression decreased by 2.7-fold with 0.0001 nmol/L tamoxifen and DHEAS. ER and PR expression were unchanged by 10 nmol/L tamoxifen. IGF-1 and IGF-2 were not expressed. IGFBP-2 and -4 expression decreased by 1.9- and 1.6-fold after DHEAS stimulus, although this was not statistically significant. DHEAS exposure, even in the presence of tamoxifen and fulvestrant, induces changes in ER and PR gene expression that may be partially responsible for breast cancer progression.

    KW - Breast cancer

    KW - Dehydroepiandosterone sulfate

    KW - Estrogen receptor

    KW - Fulvestrant

    KW - Insulin-like growth factor

    KW - Tamoxifen

    UR - http://www.scopus.com/inward/record.url?scp=4944259832&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=4944259832&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2004.06.017

    DO - 10.1016/j.amjsurg.2004.06.017

    M3 - Article

    VL - 188

    SP - 426

    EP - 428

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 4 SPEC. ISS.

    ER -